Since its inception, RECIST has undergone revisions to address its limitations and incorporate new understanding of tumor biology. RECIST 1.1, the latest version, introduced several updates, including the reduction in the number of target lesions and more precise definitions of progressive disease. These changes aim to improve the accuracy and reliability of response assessments.
